Z-LEHD-FMK TFA is a selective and irreversible inhibitor of caspase-9 , protects against lethal reperfusion injury and attenuates apoptosis. Z-LEHD-FMK TFA exhibits the neuroprotective effect in a rat model of spinal cord trauma.

Z-LEHD-FMK (20 μM; pretreated for 30 min) completely protects HCT116 and 293 cells from TRAIL-induced toxicity[1]. Z-LEHD-FMK (20 μM ; 6 h) protects normal human hepatocytes from TRAIL-induced apoptosis[1]. Apoptosis Analysis[1]Cell Line: SW480, H460, HCT116 and 293 cells Concentration: 20 μM Incubation Time: Pretreated for 30 min Result: Protected HCT116 and 293 cells from TRAIL-induced apoptosis. Western Blot Analysis[1]Cell Line: HCT116, SW480 cells Concentration: 20 μM Incubation Time: 2 h Result: Protected procaspase 3 from cleavage in HCT116 cells but not in SW480 cells, especially at the 16-h time point.

Z-LEHD-FMK (0.8 μmol/kg; i.v. for 7 d) protects neurons, glia, myelin, axons, and intracellular organelles in spinal cord injury (SCI) rats[2]. Animal Model: Male Wistar albino rats (250-350 g) with SCI[2]Dosage: 0.8 μmol/kg Administration: I.v. for 1 or 7 days Result: Decreased the mean apoptotic cell count at 24 hours and 7 days postinjury.

524746-03-0

C34H44F4N6O12

804.74

Z-LEHD-FMK TFA

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years